Compare Stocks: MDXG, NKTR, AMLX, and PGEN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$24.19 +10.7%	$17.19	$7.48 ▼ $24.36	$2.43B	-0.21	1.86 million shs	3.54 million shs
MDXG MiMedx Group	$4.18 +0.5%	$3.97	$3.03 ▼ $7.97	$606.36M	1.45	1.50 million shs	1.39 million shs
NKTR Nektar Therapeutics	$73.45 +0.5%	$66.21	$21.60 ▼ $109.00	$2.47B	1.14	720,276 shs	403,492 shs
PGEN Precigen	$6.91 +0.3%	$5.17	$1.70 ▼ $7.23	$2.46B	1.02	4.63 million shs	6.89 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	+10.71%	+16.58%	+33.13%	+64.22%	+195.36%
MDXG MiMedx Group	+0.48%	-1.30%	-0.48%	+16.11%	-42.27%
NKTR Nektar Therapeutics	+0.49%	+2.80%	-1.94%	-10.31%	+227.17%
PGEN Precigen	+0.29%	+16.33%	+25.41%	+64.13%	+277.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$24.19 +10.7%	$17.19	$7.48 ▼ $24.36	$2.43B	-0.21	1.86 million shs	3.54 million shs
MDXG MiMedx Group	$4.18 +0.5%	$3.97	$3.03 ▼ $7.97	$606.36M	1.45	1.50 million shs	1.39 million shs
NKTR Nektar Therapeutics	$73.45 +0.5%	$66.21	$21.60 ▼ $109.00	$2.47B	1.14	720,276 shs	403,492 shs
PGEN Precigen	$6.91 +0.3%	$5.17	$1.70 ▼ $7.23	$2.46B	1.02	4.63 million shs	6.89 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	+10.71%	+16.58%	+33.13%	+64.22%	+195.36%
MDXG MiMedx Group	+0.48%	-1.30%	-0.48%	+16.11%	-42.27%
NKTR Nektar Therapeutics	+0.49%	+2.80%	-1.94%	-10.31%	+227.17%
PGEN Precigen	+0.29%	+16.33%	+25.41%	+64.13%	+277.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	2.90	Moderate Buy	$25.38	4.90% Upside
MDXG MiMedx Group	2.71	Moderate Buy	$8.50	103.35% Upside
NKTR Nektar Therapeutics	2.75	Moderate Buy	$150.00	104.22% Upside
PGEN Precigen	2.33	Hold	$14.50	109.84% Upside

Current Analyst Ratings Breakdown

Latest MDXG, NKTR, AMLX, and PGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $18.00
8/3/2026	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $26.00
8/3/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
7/22/2026	NKTR Nektar Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$153.00
7/20/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $24.00
7/17/2026	PGEN Precigen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/25/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $40.00
6/8/2026	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$34.00
6/2/2026	NKTR Nektar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/28/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $14.00
5/18/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	30.79	N/A	N/A	$2.78 per share	8.70
MDXG MiMedx Group	$418.63M	1.46	$0.56 per share	7.51	$1.48 per share	2.82
NKTR Nektar Therapeutics	$55.23M	44.94	N/A	N/A	$4.41 per share	16.66
PGEN Precigen	$85.72M	28.74	N/A	N/A	$0.12 per share	57.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.50	N/A	N/A	N/A	N/A	-55.69%	-50.73%	N/A
MDXG MiMedx Group	$48.58M	$0.04	104.53	24.59	N/A	1.76%	12.09%	9.22%	N/A
NKTR Nektar Therapeutics	-$164.08M	-$8.42	N/A	N/A	N/A	-284.18%	-85.40%	-39.99%	8/13/2026 (Estimated)
PGEN Precigen	-$250.64M	-$1.04	N/A	23.03	N/A	-183.98%	423.75%	84.39%	N/A

Latest MDXG, NKTR, AMLX, and PGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	N/A	N/A	N/A	$10.43 million	N/A
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	$0.05	+$0.0621	$0.05	$27.98 million	$54.98 million
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million
5/13/2026	Q1 2026	PGEN Precigen	-$0.03	-$0.02	+$0.01	-$0.02	$20.81 million	$23.25 million
5/7/2026	Q1 2026	AMLX Amylyx Pharmaceuticals	-$0.34	-$0.37	-$0.03	-$0.37	N/A	N/A
5/7/2026	Q1 2026	NKTR Nektar Therapeutics	-$1.5824	-$1.82	-$0.2377	-$1.82	$10.69 million	$10.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	17.85	17.85
MDXG MiMedx Group	0.07	5.33	4.79
NKTR Nektar Therapeutics	N/A	10.21	10.21
PGEN Precigen	2.15	4.58	4.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
MDXG MiMedx Group	79.15%
NKTR Nektar Therapeutics	75.88%
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
MDXG MiMedx Group	2.50%
NKTR Nektar Therapeutics	2.50%
PGEN Precigen	41.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	111.19 million	99.07 million	Optionable
MDXG MiMedx Group	870	145.76 million	142.12 million	Optionable
NKTR Nektar Therapeutics	220	33.79 million	32.94 million	Optionable
PGEN Precigen	190	356.51 million	208.92 million	Optionable

MDXG, NKTR, AMLX, and PGEN Headlines

Recent News About These Companies

Precigen (NASDAQ:PGEN) Shares Gap Up After Strong Earnings

1 hour ago | americanbankingnews.com

Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement

August 6 at 4:00 PM | seekingalpha.com

HC Wainwright Predicts Precigen's Q4 Earnings (NASDAQ:PGEN)

August 6 at 7:56 AM | marketbeat.com

Precigen (NASDAQ:PGEN) Reaches New 12-Month High - Should You Buy?

August 6 at 5:59 AM | marketbeat.com

Arrowstreet Capital Limited Partnership Acquires Shares of 395,695 Precigen, Inc. $PGEN

August 6 at 3:12 AM | marketbeat.com

Precigen Inc (PGEN) (Q2 2026) Earnings Call Highlights: Revenue Surges 145% and Net Profit Achieved

August 5 at 6:43 PM | finance.yahoo.com

Precigen (NASDAQ:PGEN) Shares Gap Up on Better-Than-Expected Earnings

August 5 at 10:39 AM | marketbeat.com

HC Wainwright Reiterates Buy Rating for Precigen (NASDAQ:PGEN)

August 5 at 2:14 AM | americanbankingnews.com

Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript

August 5 at 2:00 AM | seekingalpha.com

Precigen Target of Unusually Large Options Trading (NASDAQ:PGEN)

August 5 at 1:41 AM | americanbankingnews.com

Precigen Q2 Earnings Call Highlights

August 4 at 10:02 PM | marketbeat.com

Precigen (NASDAQ:PGEN) Announces Earnings Results

August 4 at 7:55 PM | marketbeat.com

Precigen, Inc. (PGEN) Q2 Earnings and Revenues Surpass Estimates

August 4 at 6:41 PM | zacks.com

Precigen (PGEN) Stock Rises on Q2 2026 Earnings

August 4 at 5:11 PM | quiverquant.comQ

Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth

August 4 at 4:01 PM | prnewswire.com

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL)

August 4 at 1:05 PM | theglobeandmail.com

Precigen, Inc. (NASDAQ:PGEN) Given Average Recommendation of "Hold" by Brokerages

August 4 at 4:28 AM | marketbeat.com

Insider Selling: Precigen (NASDAQ:PGEN) COO Sells 33,772 Shares

August 4 at 4:21 AM | insidertrades.com

Rutul Shah Sells 33,772 Shares of Precigen (NASDAQ:PGEN) Stock

August 3, 2026 | marketbeat.com

Precigen Sees Unusually High Options Volume (NASDAQ:PGEN)

August 3, 2026 | marketbeat.com

Precigen (NASDAQ:PGEN) Earns Buy Rating from HC Wainwright

August 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG, NKTR, AMLX, and PGEN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$24.19 +2.34 (+10.71%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$23.94 -0.25 (-1.01%)

As of 08/6/2026 06:51 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

MiMedx Group NASDAQ:MDXG

$4.18 +0.02 (+0.48%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$4.18 +0.00 (+0.12%)

As of 08/6/2026 04:10 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Nektar Therapeutics NASDAQ:NKTR

$73.45 +0.36 (+0.49%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$72.78 -0.67 (-0.92%)

As of 08/6/2026 06:33 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Precigen NASDAQ:PGEN

$6.91 +0.02 (+0.29%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$6.94 +0.02 (+0.36%)

As of 08/6/2026 06:28 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDXG, NKTR, AMLX, and PGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDXG, NKTR, AMLX, and PGEN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDXG, NKTR, AMLX, and PGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG, NKTR, AMLX, and PGEN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

MiMedx Group NASDAQ:MDXG

Nektar Therapeutics NASDAQ:NKTR

Precigen NASDAQ:PGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDXG, NKTR, AMLX, and PGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDXG, NKTR, AMLX, and PGEN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDXG, NKTR, AMLX, and PGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG, NKTR, AMLX, and PGEN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

MiMedx Group NASDAQ:MDXG

Nektar Therapeutics NASDAQ:NKTR

Precigen NASDAQ:PGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools